-
The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. J. Urol. (IF 6.6) Pub Date : 2024-04-23 Anne Pelletier Cameron, Doreen E Chung, Elodi J Dielubanza, Ekene Enemchukwu, David A Ginsberg, Brian T Helfand, Penny Holland, Brian J Linder, Leila Rahimi, W Stuart Reynolds, Eric S Rovner, Lesley Souter, Anne M Suskind, Elizabeth Takacs, Blayne Welk, Ariana L Smith
The purpose of this guideline is to provide evidence-based guidance to clinicians of all specialties on the evaluation, management, and treatment of idiopathic overactive bladder (OAB). The guideline informs the reader on valid diagnostic processes and provides an approach to selecting treatment options for patients with OAB through the shared decision-making process that will maximize symptom control
-
A Phase II Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder. J. Urol. (IF 6.6) Pub Date : 2024-04-23 Sunil H Patel, Andrew T Gabrielson, Sin Chan, Deborah Schwartz, Connie Collins, Nirmish Singla, Bruce Trock, Trinity J Bivalacqua, Noah Hahn, Max R Kates
Combination intravesical gemcitabine and docetaxel (GemDoce) has demonstrated efficacy as second-line therapy for patients with bacillus Calmette-Guérin (BCG)‒unresponsive nonmuscle-invasive urothelial carcinoma of the bladder (NMIBC). In the context of widespread BCG shortages, we performed a phase 2 prospective trial to assess GemDoce for BCG-naïve NMIBC.
-
Identifying Bladder Phenotypes After Spinal Cord Injury With Unsupervised Machine Learning: A New Way to Examine Urinary Symptoms and Quality of Life. J. Urol. (IF 6.6) Pub Date : 2024-04-16 Blayne Welk, Tianyue Zhong, Jeremy Myers, John Stoffel, Sean Elliot, Sara M Lenherr, Daniel Lizotte
Patients with spinal cord injuries (SCI) experience variable urinary symptoms and QOL. Our objective was to use machine learning to identify bladder-relevant phenotypes after SCI and assess their association with urinary symptoms and QOL.
-
Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial. J. Urol. (IF 6.6) Pub Date : 2024-04-15 Hooman Djaladat, Alireza Ghoreifi, Tapas Tejura, Gus Miranda, Jie Cai, Farshad Sheybaee Moghaddam, Ileana Aldana, Rene Sotelo, Inderbir Gill, Sumeet Bhanvadia, Anne Schuckman, Mihir Desai, Monish Aron, Siamak Daneshmand, Vinay Duddalwar
We assessed the effect of prophylactic biologic mesh on parastomal hernia (PSH) development in patients undergoing cystectomy and ileal conduit (IC).
-
Bladder Exstrophy Consortium (MIBEC) After 8 Years: The Short and Intermediate Term Outcomes. J. Urol. (IF 6.6) Pub Date : 2024-04-15 Dana A Weiss, Travis W Groth, Suhaib Abdulfattah Abdulfattah, Sahar Eftekharzadeh, Ted Lee, Richard Lee, Douglas A Canning, John V Kryger, Aseem R Shukla, Elizabeth B Roth, Michael E Mitchell, Joseph G Borer
Bladder exstrophy (BE) poses challenges both during the surgical repair and throughout follow-up. In 2013, a multi-institutional BE consortium was initiated, which included utilization of unified surgical principles for the complete primary repair of exstrophy (CPRE), real time coaching, ongoing video capture and review of video footage, prospective data collection, and routine patient data analysis
-
Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study. J. Urol. (IF 6.6) Pub Date : 2024-04-11 Hannah Kay, Sarah N Silver, Angela B Smith, Ramsankar Basak, Kimberly Shoenbill, Deborah Usinger, Adam O Goldstein, Richard S Matulewicz, Ronald Chen, Marc A Bjurlin
Cigarette smoking is the most common risk factor for the development of bladder cancer (BC), yet there is a paucity of data characterizing the relationship between smoking status and longitudinal Health Related Quality of Life (HRQoL) outcomes in patients with BC. We examined the association between smoking status and HRQoL among patients with BC.
-
Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy. J. Urol. (IF 6.6) Pub Date : 2024-04-11 Marie-Pier St-Laurent, George Acland, Sarah N Hamilton, Jeremy Hamm, Katherine Sunderland, Peter C Black, Michael McKenzie, Mira Keyes, Stacy Miller, Martin E Gleave, Scott Tyldesley
Second malignancy is a rare but potentially lethal event after prostate brachytherapy, but data remain scarce on its long-term risk. The objective of this study is to estimate the number of pelvic second malignancies following brachytherapy compared to prostatectomy (RP).
-
An Economic Evaluation of a Web-Based Management Support System for Children With Urinary Incontinence: The eADVICE Trial. J. Urol. (IF 6.6) Pub Date : 2024-04-11 Amy Von Huben, Martin Howell, Deborah Richards, Sana Hamilton, Kirsten Howard, Armando Teixeira-Pinto, Jonathan C Craig, Chris Seton, Karen Waters, Aniruddh Deshpande, Karen M Scott, Patrina H Y Caldwell
Children who require specialist outpatient care typically wait substantial periods during which their condition may progress, making treatment more difficult and costly. Timely and effective therapy during this period may reduce the need for lengthy specialist care. This study evaluated the cost-effectiveness of an individualized, evidence-informed, web-based program for children with urinary incontinence
-
Burnout in Urological Education: An In-Depth Study of Residents and Fellows in the 2021 AUA Census. J. Urol. (IF 6.6) Pub Date : 2024-04-11 Andrew Harris, Roei Golan, Kate Kraft, Amanda North, Parth Modi, William Meeks, Emily Galen, Alexis Helsel, Kevin Koo
To explore the current trends in burnout, career choice regret, and well-being needs among urology residents and fellows, with specific emphasis on identifying key factors associated with burnout.
-
Should a Refluxing Internal Diversion Be Considered a Temporizing Procedure? Extended Follow-Up and Outcomes After Side-to-side Ureterovesicostomy for Primary Obstructive Megaureter in Young Children. J. Urol. (IF 6.6) Pub Date : 2024-04-11 Adree Khondker, Mandy Rickard, Jin Kyu Kim, Julianne Richter, Margarita Chancy, Kay Rivera, Joana Dos Santos, Michael Chua, Armando J Lorenzo
To describe long-term outcomes, including urinary tract infections (UTIs) and need for reimplantation, after ureterovesicostomy (UV) as a lasting surgical procedure for children with primary obstructed megaureter (POM).
-
Distribution and Positive Predictive Value of Follicle Stimulating Hormone (FSH) Levels Among Non-azoospermic Men. J. Urol. (IF 6.6) Pub Date : 2024-04-11 Solomon Hayon, Sai Kaushik Sr Kumar, Daniel Greenberg, Xinlei Mi, Richard J Fantus, Robert E Brannigan, Joshua A Halpern
To characterize the distribution of follicle stimulating hormone (FSH) in fertile and subfertile non-azoospermic men, and to determine the ability of various FSH thresholds to predict fertility status.
-
Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer. J. Urol. (IF 6.6) Pub Date : 2024-04-10 Florian Rumpf, Anna Plym, Jane B Vaselkiv, Kathryn L Penney, Mark A Preston, Adam S Kibel, Lorelei A Mucci, Keyan Salari
Family history and germline genetic risk single nucleotide polymorphisms (SNPs) have been separately shown to stratify lifetime risk of prostate cancer. Here, we evaluate the combined prognostic value of family history of prostate and other related cancers and germline risk SNPs among patients with favorable-risk prostate cancer.
-
Conversion to Radical Nephrectomy From Robotic Partial Nephrectomy Is Most Commonly Due to Anatomic and Oncologic Complexity. J. Urol. (IF 6.6) Pub Date : 2024-04-09 Yuzhi Wang, Samantha Wilder, Mohit Butaney, Mahmoud Hijazi, David Gandham, Monica Van Til, Benjamin Goldman, Ji Qi, Mahin Mirza, Anna Johnson, Michael Rudoff, David Wenzler, Craig G Rogers, Brian R Lane
Partial nephrectomy is standard-of-care treatment for small renal masses. As utilization of partial nephrectomy increases and includes larger and complex tumors, the risk of conversion to radical nephrectomy likely increases. We evaluated incidence and reason for conversion to radical nephrectomy in patients scheduled for partial nephrectomy by surgeons participating in MUSIC (the Michigan Urologic
-
A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy. J. Urol. (IF 6.6) Pub Date : 2024-04-09 Hongyang Qian, Chenfei Chi, Thibault Tricard, Yinjie Zhu, Liang Dong, Yanqing Wang, Jianjun Sha, Jiayi Wang, Zehua Ma, Yan Wang, Jiazhou Liu, Baijun Dong, Jiahua Pan, Wei Xue
Benefits of docetaxel-based neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP) remain largely unknown. We explored whether docetaxel-based NCHT would bring pathological benefits and improve biochemical progression-free survival (bPFS) over neoadjuvant hormonal therapy (NHT) in locally advanced prostate cancer.
-
Deep Phenotyping the Anterior Urethral Stricture: Characterizing the Relationship Between Inflammation, Fibrosis, Patient History and Disease Pathophysiology. J. Urol. (IF 6.6) Pub Date : 2024-04-09 Wade R Gutierrez, Yi Luo, Laila Dahmoush, Jacob J Oleson, Charles H Schlaepfer, Benjamin N Breyer, Sean P Elliott, Jeremy B Myers, Alex J Vanni, Denise Juhr, Katherine N Christel, Bradley A Erickson
Anterior urethral stricture disease (aUSD) is a complex, heterogeneous condition which is idiopathic in origin for most men. This gap in knowledge rarely affects the current management strategy for aUSD, as urethroplasty does not generally consider etiology. However, as we transition towards personalized, minimally invasive treatments for aUSD and begin to consider aUSD prevention strategies, disease
-
Phase 1b Trial Evaluating Tolerability and Activity of Targeted FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma. J. Urol. (IF 6.6) Pub Date : 2024-04-04 Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Rhenita Amirtharaj, Lianchun Xiao, Suzanne Lange, Dzifa Y Duose, Shufang Wang, Sumanta Pal, Matthew T Campbell
We initiated a biomarker-informed preoperative study of infigratinib, a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations.
-
Patient Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy. J. Urol. (IF 6.6) Pub Date : 2024-04-04 Rachel A Moses, Alexandra E Hunter, Eileen R Brandes, Ziyin Zhang, Judy R Rees, Janet L Peacock, William Bihrle, Kinjal Sethuraman, Lindell K Weaver, Jay C Buckey
To determine changes in patient reported hematuria and urinary symptoms after hyperbaric oxygen (HBO2) treatment for radiation cystitis (RC).
-
Limitations of Parenchymal Volume Analysis for Estimating Split Renal Function and New Baseline GFR After Radical Nephrectomy. J. Urol. (IF 6.6) Pub Date : 2024-03-08 Kieran Lewis, Eran N Maina, Carlos Munoz Lopez, Nityam Rathi, Worapat Attawettayanon, Akira Kazama, Jihad Kaouk, Georges-Pascal Haber, Mohamad Eltemamy, Venkatesh Krishnamurthi, Robert Abouassaly, Christopher J Weight, Steven C Campbell
Accurately predicting new baseline-glomerular-filtration rate (NBGFR) after radical nephrectomy (RN) can improve counseling about RN vs partial nephrectomy. Split-renal-function (SRF)-based models are optimal, and differential parenchymal volume analysis (PVA) is more accurate than nuclear renal scans (NRS) for this purpose. However, there is minimal data regarding the limitations of PVA. Our objective
-
Gabapentin for Post-operative Pain Control and Opioid Reduction in Scrotal Surgery: A Randomized Controlled Clinical Trial. J. Urol. (IF 6.6) Pub Date : 2024-02-21 Nahid Punjani, Jessica A Marinaro, Caroline Kang, Jonathan Gal, Brady Rippon, Rohan Jotwani, Roniel Weinberg, Peter N Schlegel
To assess the safety and efficacy of gabapentin in reducing post-operative pain among patients undergoing scrotal surgery for male infertility by conducting a randomized, double-blind, placebo-controlled trial.
-
Timing of Testicular Biopsy in Relation to Oocyte Retrieval and the Outcomes of Intracytoplasmic Sperm Injection. J. Urol. (IF 6.6) Pub Date : 2024-02-20 Lily Ng, Olena M Kocur, Philip Xie, Stephanie Cheung, Peter Schlegel, Zev Rosenwaks, Gianpiero D Palermo
To evaluate microscopic testicular sperm extraction (micro-TESE) timing relative to oocyte retrieval on intracytoplasmic sperm injection (ICSI) outcome.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J. Urol. (IF 6.6) Pub Date : 2024-02-19 Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, Brian F Chapin, David Y T Chen, Heather H Cheng, Roger Chou, Heather A Jacene, Sophia C Kamran, Sennett K Kim, Erin Kirkby, Amy N Luckenbaugh, Ben J Nathanson, Yaw A Nyame, Edwin M Posadas, Phuoc T Tran, Ronald C Chen
The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part I of a three-part series focusing on treatment decision-making at the time of suspected biochemical recurrence (BCR) after radical
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J. Urol. (IF 6.6) Pub Date : 2024-02-14 Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, Brian F Chapin, David Y T Chen, Heather H Cheng, Roger Chou, Heather A Jacene, Sophia C Kamran, Sennett K Kim, Erin Kirkby, Amy N Luckenbaugh, Ben J Nathanson, Yaw A Nyame, Edwin M Posadas, Phuoc T Tran, Ronald C Chen
The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a 3-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J. Urol. (IF 6.6) Pub Date : 2024-02-14 Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, Brian F Chapin, David Y T Chen, Heather H Cheng, Roger Chou, Heather A Jacene, Sophia C Kamran, Sennett K Kim, Erin Kirkby, Amy N Luckenbaugh, Ben J Nathanson, Yaw A Nyame, Edwin M Posadas, Phuoc T Tran, Ronald C Chen
The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part III of a three-part series focusing on evaluation and management of suspected non-metastatic recurrence after radiotherapy (RT)
-
Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18F-DCFPyL‒Prostate-Specific Membrane Antigen‒Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients. J. Urol. (IF 6.6) Pub Date : 2024-02-01 Rui Bernardino, Rashid K Sayyid, Katherine Lajkosz, Zizo Al-Daqqaq, Raj Tiwari, Jessica Cockburn, Ricardo Leão, Ur Metser, Alejandro Berlin, Theodorus van der Kwast, Neil E Fleshner
Intraductal prostate cancer (IDC) is linked to unfavorable oncologic outcomes, marked by distinctive cellular intrinsic pathway changes and intricate immunosuppressive microenvironments that could impact the way cancer spreads. The aim of this study was to determine whether the presence of IDC in prostate biopsy specimens obtained from patients before primary prostate cancer (PCa) treatment is associated
-
Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression. J. Urol. (IF 6.6) Pub Date : 2024-02-01 Misty D Bechtel, Carrie Michel, Pugazhendhi Srinivasan, Prabhakar Chalise, William P Parker, Moben Mirza, Brantley Thrasher, Heather D Gibbs, John DiGiovanni, Jill Hamilton-Reeves
Excess body and visceral fat increase the risk of death from prostate cancer (PCa). This phase II study aimed to test whether weight reduction by > 5% total body weight counteracts obesity-driven PCa biomarkers.
-
Nursing Workloads and Lower Urinary Tract Symptoms Among Chinese Female Nurses: The Mediating Role of Delayed Voiding Behaviours. J. Urol. (IF 6.6) Pub Date : 2024-01-29 Yongjuan Rao, Chen Wu, Dongjuan Xu, Yongjian Zhu, Junxiu Ma, Jing Mou, Jie Gao, Jieqiong Ren, Ming Li, Kefang Wang
Lower urinary tract symptoms (LUTS) challenge to build a healthy nursing workforce. Nurses confront various objective and subjective nursing workloads which contribute to their LUTS, but less is known about how nursing workloads influence their LUTS. This study is designed to test hypotheses that delayed voiding behaviours mediate the relationships between nursing workloads and LUTS in female nurses
-
Multi-Institutional Outcomes of Dorsal Onlay Buccal Mucosal Graft Urethroplasty in Patients With Postprostatectomy, Postradiation Anastomotic Stenosis. J. Urol. (IF 6.6) Pub Date : 2024-01-26 Joshua Sterling, Jay Simhan, Brian J Flynn, Paul Rusilko, W A Franca, Erick A Ramirez, Javier C Angulo, Francisco E Martins, Hiren V Patel, Margaret Higgins, Daniel Swerdloff, Dmitriy Nikolavsky
The treatment of urethral stenosis after a combination of prostatectomy and radiation therapy for prostate cancer is understudied. We evaluate the clinical and patient-related outcomes after dorsal onlay buccal mucosal graft urethroplasty (D-BMGU) in men who underwent prostatectomy and radiation therapy.
-
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J. Urol. (IF 6.6) Pub Date : 2024-01-24 Jeffrey M Holzbeierlein, Brooke R Bixler, David I Buckley, Sam S Chang, Rebecca Holmes, Andrew C James, Erin Kirkby, James M McKiernan, Anne K Schuckman
The purpose of this American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline amendment is to provide a useful reference on the effective evidence-based treatment strategies for non-muscle invasive bladder cancer (NMIBC).
-
Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy Using Artificial Intelligence. J. Urol. (IF 6.6) Pub Date : 2024-01-24 Abhinav Khanna, Alenka Antolin, Omri Bar, Danielle Ben-Ayoun, Maya Zohar, Stephen A Boorjian, Igor Frank, Paras Shah, Vidit Sharma, R Houston Thompson, Tamir Wolf, Dotan Asselmann, Matthew Tollefson
The widespread use of minimally invasive surgery generates vast amounts of potentially useful data in the form of surgical video. However, raw video footage is often unstructured and unlabeled, thereby limiting its use. We developed a novel computer-vision algorithm for automated identification and labeling of surgical steps during robotic-assisted radical prostatectomy (RARP).
-
Cognitive Behavioral Therapy for Chronic Pelvic Pain: What Is It and Does It Work? J. Urol. (IF 6.6) Pub Date : 2024-01-16 Jeffrey M Lackner, J Quentin Clemens, Christopher Radziwon, Teresa L Danforth, Tova S Ablove, Susan S Krasner, Alison M Vargovich, Patricia C O'Leary, Tracy Marotto, Bruce D Naliboff
Urologic chronic pelvic pain syndrome (UCPPS), which encompasses interstitial cystitis/bladder pain syndrome in women and men, and chronic prostatitis/chronic pelvic pain syndrome in men, is a common, often disabling, urological disorder that is neither well understood nor satisfactorily treated with medical treatments. The past 25 years have seen the development and validation of a number of behavioral
-
Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy? J. Urol. (IF 6.6) Pub Date : 2024-01-10 Jose M Flores, Emily Vertosick, Lawrence C Jenkins, John Cooper, Nicole Benfante, Daniel Sjoberg, Andrew J Vickers, James A Eastham, Vincent P Laudone, Peter T Scardino, Christian J Nelson, John P Mulhall
There have been conflicting studies on the association between phosphodiesterase type 5 inhibitor (PDE5i) use and biochemical recurrence (BCR) following radical prostatectomy (RP). Our aim was to determine whether PDE5i drug exposure after RP increases the risk of BCR in patients undergoing RP.
-
Alkaline Water: Help or Hype for Uric Acid and Cystine Urolithiasis? J. Urol. (IF 6.6) Pub Date : 2024-01-09 Paul Piedras, Andrei D Cumpanas, Amanda McCormac, Seyed Amiryaghoub M Lavasani, Antonio R H Gorgen, Allen Rojhani, Minh-Chau Vu, Rohit Bhatt, John Asplin, Zachary E Tano, Jaime Landman, Ralph V Clayman, Roshan M Patel
The consumption of alkaline water, water with an average pH of 8 to 10, has been steadily increasing globally as proponents claim it to be a healthier alternative to regular water. Urinary alkalinization therapy is frequently prescribed in patients with uric acid and cystine urolithiasis, and as such we analyzed commercially available alkaline waters to assess their potential to increase urinary pH
-
Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men. J. Urol. (IF 6.6) Pub Date : 2023-12-27 Helen Y Hougen, Daniel D Sjoberg, Jamie Thomas, Brandon A Mahal, Andrew J Vickers, Sanoj Punnen
Black men face a higher incidence of high-risk prostate cancer (PCa) compared with non-Black men. While the 4Kscore is a widely utilized commercial test for PCa risk assessment, it does not currently account for racial differences. The aim of this study is to describe and validate a prespecified race coefficient for the 4Kscore with the goal of improving the accuracy of this test for Black men.
-
A Randomized Controlled Trial of a Web-Based Management Support System for Children with Urinary Incontinence: The eADVICE Trial. J. Urol. (IF 6.6) Pub Date : 2023-12-27 Patrina H Y Caldwell, Deborah Richards, Sana Hamilton, Amy Von Huben, Armando Teixeira-Pinto, Martin Howell, Kirsten Howard, Jonathan C Craig, Chris Seton, Karen Waters, Aniruddh Deshpande, Karen M Scott
Children referred to specialist outpatient clinics by primary-care providers often have long waiting times before being seen. We assessed whether an individualized, web-based, evidence-informed management support for children with urinary incontinence while waiting reduced requests for specialist appointments.
-
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification. J. Urol. (IF 6.6) Pub Date : 2023-12-26 Leander Van Neste, Ricardo Henao, Kirk J Wojno, Jorge Signes, Jessica DeHart, Angela Busta, Elyse Marriott, Marian Willing, Andrea Argentini, Patrick M Hurley, Howard Korman, Jason Hafron, Mathew Putzi, Chris M Pieczonka, Lawrence I Karsh, David S Morris, Amin I Kassis, Philip W Kantoff
Less invasive decision support tools are desperately needed to identify occult high-risk disease in men with prostate cancer (PCa) on an active surveillance (AS). For a variety of reasons, many men on AS with low or intermediate risk disease forgo the necessary repeat surveillance biopsies needed to identify potentially higher risk PCa. Here, we describe the development of a blood-based immunocyte
-
Comparative Analyses and Ablation Efficiency of Thulium Fiber Laser by Stone Composition. J. Urol. (IF 6.6) Pub Date : 2023-12-22 Jeffrey Johnson, Justin Lee, Miyad Movassaghi, David Han, Srinath-Reddi Pingle, James Williams, Michael Schulster, Prakash Gorroochurn, Yinming Shao, Ojas Shah
There is limited data on ablation effects of thulium fiber laser (TFL) settings with varying stone composition. Similarly, little is known surrounding the photothermal effects of TFL lithotripsy regarding the chemical and structural changes after visible char formation. We aim to understand the TFL's ablative efficiency across various stone types and laser settings, while simultaneously investigating
-
Risk of Biochemical Recurrence in Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension Treated with Radical Prostatectomy. J. Urol. (IF 6.6) Pub Date : 2023-12-18 Michael E Rezaee, Maximilian Pallauf, Sean A Fletcher, Misop Han, Christian P Pavlovich, Chien-Kuang Cornelia Ding, Jonathan I Epstein, Mohamad E Allaf, Bruce J Trock, Nirmish Singla
To examine the association of extraprostatic extension (EPE) with biochemical recurrence (BCR) separately in men with grade group 1 (GG1) and GG2 prostate cancer (PCa) treated with radical prostatectomy.
-
Urologic Chronic Pelvic Pain Syndrome Flares: A Comprehensive, Systematic Review and Meta-Analysis of the Peer-Reviewed Flare Literature. J. Urol. (IF 6.6) Pub Date : 2023-12-18 Emily S Barker, Kimberley Chiu, Victoria L Brown, Haidy Morsy, Lauren H Yaeger, Arya Catna, Ratna Pakpahan, Robert Moldwin, Barbara Shorter, Jerry L Lowder, H Henry Lai, Siobhan Sutcliffe
To systematically review and summarize the peer-reviewed literature on urologic chronic pelvic pain syndrome (UCPPS) flares, including their terminology, manifestation, perceived triggers, management and prevention strategies, impact on quality of life, and insights into pathophysiologic mechanisms, as a foundation for future empirical research.
-
Affirming Long-Term Outcomes after Contemporary Urethroplasty: The Adverse Impact of Increasing Stricture Length, Lichen Sclerosus, Radiation and Infectious Strictures. J. Urol. (IF 6.6) Pub Date : 2023-12-18 Carlos Ignacio Calvo, Kai Fender, Nathan Hoy, Keith Rourke
There is a paucity of reported long-term outcomes after contemporary urethroplasty. Our objective is to determine the long-term success of modern urethroplasty and identify factors associated with stricture recurrence in this context.
-
Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies. J. Urol. (IF 6.6) Pub Date : 2023-12-15 M P Mannas, F M Deng, A Ion-Margineanu, D Jones, D Hoskoppal, J Melamed, S Pastore, C Freudiger, D A Orringer, S S Taneja
Stimulated Raman histology is an innovative technology that generates real-time, high-resolution microscopic images of unprocessed tissue, significantly reducing prostate biopsy interpretation time. This study aims to evaluate the ability for an artificial intelligence convolutional neural network to interpretate prostate biopsy histologic images created with stimulated Raman histology.
-
Prospective Multicenter Evaluation of Pain Before and After Removal of Nonobstructing Renal Calculi: A CoRE Initiative. J. Urol. (IF 6.6) Pub Date : 2023-12-15 Naeem Bhojani, Daniel Wollin, Marawan M El Tayeb, Kymora B Scotland, John Knoedler, Karen L Stern, David-Dan Nguyen, Marcelino Rivera, Michael S Borofsky, Noah Canvasser, Seth K Bechis, Ryan S Hsi
Flank pain associated with stone disease is typically caused by a stone that obstructs urine flow. However, it is plausible that nonobstructing kidney stones may still cause pain. We performed a multicenter, observational trial to evaluate whether treatment of small nonobstructing calyceal stones improves pain and kidney stone-specific health-related quality of life.
-
Reporting of Harms in Randomized Controlled Trials Published in Urology Journals: An Updated Analysis. J. Urol. (IF 6.6) Pub Date : 2023-12-08 Reece M Anderson, Andriana Peña, Trevor Magee, Del Perkins, Bradley S Johnson, Rodney H Breau, Matt Vassar
Harms are often overlooked, but important, outcomes of randomized controlled trial reporting. Our goal was to determine if harms reporting has improved in high-impact urology journals.
-
Missing the Mark? US News & World Report Urology Specialty Rankings Do Not Assess the Majority of Urologic Care. J. Urol. (IF 6.6) Pub Date : 2023-11-30 Timothy D Lyon,Ugochukwu C Ugwuowo,Benjamin D Pollock
-
Reviewer of the Month, Steven C. Campbell. J. Urol. (IF 6.6) Pub Date : 2023-11-28 Steven C Campbell
-
What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances". J. Urol. (IF 6.6) Pub Date : 2023-11-27 Daniel D Joyce,Christopher P Filson,Lindsey A Herrel
-
Innovation and Progress for Screening and Management of Localized Prostate Cancer-What an Exciting Time. J. Urol. (IF 6.6) Pub Date : 2023-11-27 Jeffrey J Tosoian,Alice Yu,Wayne G Brisbane
-
Comparison of Genomic Inflation Estimates in Genome-Wide Association Studies Using Genetically-Identified Ancestry versus Self-Identified Race/Ethnicity in Prostate Cancer Patients in ELLIPSE Cohort. J. Urol. (IF 6.6) Pub Date : 2023-11-27 Meghana S Pagadala,Stephen Ryan,Hannah Carter,Juan Javier-DesLoges
-
Practical Use of Self-Adjusted Nitrous Oxide (SANO) During Transrectal Prostate Biopsy: A Double-Blind Randomized-Control Trial. J. Urol. (IF 6.6) Pub Date : 2023-11-20 Abigail J Escobar, Suprita Krishna, K Mikayla Flowers, Alejandro Abello, Boris Gershman, Andrew A Wagner, Peter Chang, Ruslan Korets, Christopher J Mistretta, Kristen L Schreiber, Aria F Olumi, Heidi Rayala
Transrectal prostate biopsy is a common ambulatory procedure that can result in pain and anxiety for some men. Low-dose, adjustable nitrous oxide is increasingly being used to improve experience of care for patients undergoing painful procedures. This study seeks to evaluate the efficacy and safety of low dose (<45%) nitrous oxide, which has not been previously established for transrectal prostate
-
Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. J. Urol. (IF 6.6) Pub Date : 2023-11-17 Badar M Mian, Paul J Feustel, Asef Aziz, Ronald P Kaufman, Adrien Bernstein, Svetlana Avulova, Hugh A G Fisher
Transrectal prostate biopsy has come under scrutiny due to potential for post-biopsy infections and transperineal prostate biopsy is being offered as the safer alternative. However, there is a lack of randomized comparative studies. Our goal was to directly evaluate infectious and noninfectious complications following the 2 biopsy procedures.
-
Feasibility, Acceptability, and Outcomes of a Mobile Health Tool for Radical Cystectomy Recovery. J. Urol. (IF 6.6) Pub Date : 2023-11-16 Kristin Weiss, Obafunbi Abimbola, Dana Mueller, Ramsankar Basak, Ethan Basch, Taylor Parisse, Judy Hamad, Matthew Nielsen, Hung-Jui Tan, Eric Wallen, Marc Bjurlin, Angela B Smith
Postoperative education and symptom tracking are essential following cystectomy to reduce readmission rates and information overload. To address these issues, an internet-based tool was developed to provide education, alerts, and symptom tracking. We aimed to evaluate the tool's feasibility, acceptability, and impact on complication and readmission rates.
-
The Evolution of THE Journal: Enhancing the JU Experience for all Constituents. J. Urol. (IF 6.6) Pub Date : 2023-11-10 D Robert Siemens,Phillip Pierorazio,Jennifer Regala
-
Rises in Hematocrit is Associated with an Increased Risk of Major Adverse Cardiac Events in Men Starting Testosterone Therapy - A Retrospective Cohort Claims Database Analysis. J. Urol. (IF 6.6) Pub Date : 2023-11-10 Taylor P Kohn, Pranjal Agrawal, Jesse Ory, Joshua Hare, Ranjith Ramasamy
Elevated hematocrit (Hct) can result in increased risk of major adverse cardiac events (MACE) in men receiving testosterone therapy (TTh). However, the impact of the magnitude of the change in Hct from baseline after starting TTh has never been assessed.
-
Can MRI Help Inform Which Men With a History of Multifocal High-Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer? J. Urol. (IF 6.6) Pub Date : 2023-11-06 Michael S Sessine,Codrut S Radoiu,Ji Qi,Corinne Labardee,Frank Burks,Arvin K George,Brian R Lane,Kenneth Lim,Ali Dabaja,Todd M Morgan,Michael L Cher,Alice M Semerjian,Kevin B Ginsburg
PURPOSE We investigated the association of MRI findings in men with a previous diagnosis of atypical small acinar proliferation (ASAP) or multifocal high-grade intraepithelial neoplasia (HGPIN) with pathologic findings on repeat biopsy. MATERIALS AND METHODS We retrospectively reviewed patients with ASAP/multifocal HGPIN undergoing a repeat biopsy in the Michigan Urological Surgery Improvement Collaborative
-
A Pilot Study of the Effect of Transcutaneous Spinal Cord Stimulation on Micturition-Related Brain Activity and Lower Urinary Tract Symptoms After Stroke. J. Urol. (IF 6.6) Pub Date : 2023-11-06 Evgeniy I Kreydin,Aidin Abedi,Veronica Stefania Montero,Luis Morales,Rita Jen,Laura Perez,Anibal Rincon,Priya Kohli,Charles Y Liu,David A Ginsberg,Parag Gad,V Reggie Edgerton,Kay Jann
PURPOSE Transcutaneous spinal cord stimulation (TSCS) is a novel neuromodulation modality developed to promote functional restoration in patients with neurological injury or disease. Previous pilot data suggest that lower urinary tract dysfunction (LUTD) due to stroke may be partially alleviated by TSCS. In this study, we examine the mechanism of this effect by evaluating bladder-related brain activity
-
Pathological Findings in Fetuses Terminated for Suspected Lower Urinary Tract Obstruction: Experience From a High-Risk Fetal Center in Canada. J. Urol. (IF 6.6) Pub Date : 2023-11-03 Juliane Richter,Mandy Rickard,Hayley Good,Jin K Kim,Patrick Shannon,Joana Dos Santos,Michael E Chua,Armando J Lorenzo,Tim Van Mieghem,Shiri Shinar
PURPOSE Pregnancies complicated by prenatally suspected lower urinary tract obstruction (LUTO) can be associated with high rates of terminations due to potentially poor outcomes. Herein, we assessed autopsy findings of fetuses terminated for suspected LUTO to evaluate the prenatal diagnostic accuracy and spectrum of underlying pathologies. MATERIALS AND METHODS We performed a retrospective review of
-
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J. Urol. (IF 6.6) Pub Date : 2023-11-03 Akshay Sood,Jan K Rudzinski,Craig V Labbate,Patrick J Hensley,Kelly K Bree,Charles C Guo,Omar Alhalabi,Matthew T Campbell,Arlene O Siefker-Radtke,Neema Navai,Colin P N Dinney,Jianjun Gao,Ashish M Kamat
PURPOSE The treated natural history of nonmetastatic plasmacytoid variant of bladder cancer (PV-BCa) is poorly understood owing to its rarity. We sought to examine the disease recurrence and metastasis patterns in this select group of patients in order to identify opportunities for intervention. MATERIALS AND METHODS We conducted a natural language processing algorithm-augmented retrospective chart
-
Development and Validation of a Prostate Biopsy Risk Calculator in Black Men. J. Urol. (IF 6.6) Pub Date : 2023-11-02 Neil A Mistry,Zequn Sun,Jamila Sweis,Cordero McCall,Norma Marshall,Bernice Ofori,Courtney M P Hollowell,Rick A Kittles,Edward M Schaeffer,Michael Abern,Peter Gann,Adam B Murphy
PURPOSE We sought to develop and validate a prostate biopsy risk calculator for Black men and compare it with the Prostate Cancer Prevention Trial version 2.0, Prostate Biopsy Collaborative Group, and Kaiser Permanente Prostate Cancer Risk Calculators for the detection of Gleason Grade Group (GG) ≥ 2 prostate cancer (PCa). MATERIALS AND METHODS We prospectively recruited 2 cohorts of men undergoing
-
Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting. J. Urol. (IF 6.6) Pub Date : 2023-11-01 Daniel R Greenberg,Evan J Panken,Channa Amarasekera
-
Efficient and Accurate CT-based Stone Volume Determination: Development of an Automated Artificial Intelligence Algorithm. J. Urol. (IF 6.6) Pub Date : 2023-10-27 Andrei D Cumpanas, Chanon Chantaduly, Kalon L Morgan, Wei Shao, Antonio R H Gorgen, Candices Minh Tran, Yi Xi Wu, Amanda McCormac, Zachary E Tano, Roshan M Patel, Peter Chang, Jaime Landman, Ralph V Clayman
Given the shortcomings of current stone burden characterization (maximum diameter or ellipsoid formulas), we sought to investigate the diagnostic accuracy and precision of a University of California, Irvine (UCI) developed artificial intelligence (AI) algorithm for determining stone volume determination.
-
Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study. J. Urol. (IF 6.6) Pub Date : 2023-10-24 James P Daniels,James Mirocha,Michie Adjei,Daniel Moreira,Stephen J Freedland
PURPOSE Though the pathogenesis of benign prostatic hyperplasia is unclear, it was previously believed that increasing androgen levels contributed, though not all data support this idea. We tested if elevated serum testosterone or dihydrotestosterone were risk factors for lower urinary tract symptoms incidence in asymptomatic men and for lower urinary tract symptoms progression in symptomatic men.